Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN) announced today the ongoing development of a Predictive Structural Biology (PSB) Infrastructure Platform designed to computationally identify the functional interaction sites of proteins, which are of substantial importance for the rational design of novel drugs. The current application of this new infrastructure capability aims at enhanced discovery of functional monoclonal antibodies in cancer and immunology, Compugen’s core areas of focus.
Help employers find you! Check out all the jobs and post your resume.
TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN) announced today the ongoing development of a Predictive Structural Biology (PSB) Infrastructure Platform designed to computationally identify the functional interaction sites of proteins, which are of substantial importance for the rational design of novel drugs. The current application of this new infrastructure capability aims at enhanced discovery of functional monoclonal antibodies in cancer and immunology, Compugen’s core areas of focus.
Help employers find you! Check out all the jobs and post your resume.
